Pharma Mar Net Income 2019-2021 | PHMMF

Pharma Mar net income from 2019 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Pharma Mar Annual Net Income
(Millions of US $)
2020 $157
2019 $-13
2018 $-7
2017 $-30
2016 $-27
2015 $7
Pharma Mar Quarterly Net Income
(Millions of US $)
2021-06-30
2021-03-31 $29
2020-03-31 $78
2019-03-31 $-12
2018-03-31 $-2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.308B
Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company's product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81